Tofersen
Oligonucleotide
Overview
Tofersen is a oligonucleotide active pharmaceutical ingredient (ChEMBL CHEMBL3833346).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Tofersen expires 1 Apr 2035 and exclusivity 25 Apr 2030. Generic API sourcing typically opens up once these lapse.
Verified Supplier Partner
Do you supply Tofersen? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.